# Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)

> **NCT07565324** · PHASE2 · NOT_YET_RECRUITING · sponsor: **National Taiwan University Hospital** · enrollment: 54 (estimated)

## Conditions studied

- HER-2 Positive Breast Cancer

## Interventions

- **DRUG:** Lipo-Dox®
- **DRUG:** Cyclophosphamide
- **DRUG:** Trastuzumab (Herceptin)
- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT07565324
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2029-12-31
- **Final completion:** 2032-12-31
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07565324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07565324, "Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07565324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*